摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-5-甲氧基喹啉 | 1416438-38-4

中文名称
3-溴-5-甲氧基喹啉
中文别名
——
英文名称
3-bromo-5-methoxyquinoline
英文别名
——
3-溴-5-甲氧基喹啉化学式
CAS
1416438-38-4
化学式
C10H8BrNO
mdl
——
分子量
238.084
InChiKey
ZWDNTOJIDPGGDV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    22.1
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    3-溴-5-甲氧基喹啉二甲基二硫 、 在 氯化铵二氯甲烷 作用下, 以 四氢呋喃 为溶剂, 反应 3.75h, 生成 5-methoxy-3-methylthioquinoline
    参考文献:
    名称:
    HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS
    摘要:
    本发明涉及一种化合物,其包含至少一个基团C═Y,其中Y为O或S,以及一个可氧化且不可质子化的氮原子N,其中在氧化时,基团C═Y的至少一个碳原子与氮原子之间的距离(d)在0.3至0.8纳米之间。本发明涉及由公式G定义的新杂环化合物及其制备方法,涉及包含它们的制药组合物以及它们在治疗神经退行性或阿尔茨海默病方面的用途。
    公开号:
    US20090062279A1
  • 作为产物:
    描述:
    3-(tert-butoxycarbonylamino)-5-methoxyquinoline 在 氢溴酸 、 sodium nitrite 作用下, 以 为溶剂, 反应 1.0h, 生成 3-溴-5-甲氧基喹啉
    参考文献:
    名称:
    WO2006/103120
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • [EN] 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PIPÉRIDINE 1,4-SUBSTITUÉS
    申请人:CEPHALON INC
    公开号:WO2016205633A1
    公开(公告)日:2016-12-22
    Described herein are 1,4-substituted piperidine compounds according to Formula (I) that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    本文描述了按照式(I)的1,4-取代哌啶化合物,这些化合物已经表现出作为脂肪酸合成酶抑制剂的活性。本文还描述了含有所述1,4-取代哌啶化合物的药物组合物,以及通过给予所述化合物或药物配方中的一个或多个来治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述化合物的方法,包括所述的1,4-取代哌啶化合物和在这些合成中有用的合成中间体。
  • Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
    申请人:Insa Rouen
    公开号:US07977354B2
    公开(公告)日:2011-07-12
    The invention is related to compound which comprises at least one radical C═Y, Y being O or S, and an oxidable and non protonable nitrogen atom N wherein the distance (d) between the at least one carbon atom of the radical group C═Y and the nitrogen atom, when oxidized, is comprised between 0.3 and 0.8 nanometers. The invention is related to new heterocyclic compounds defined by formula G, their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of neurodegenerative or Alzheimer disease.
    该发明涉及一种化合物,其包含至少一个基团C═Y,其中Y为O或S,以及一个可氧化且非质子化的氮原子N,其中当氧化时,基团C═Y中至少一个碳原子与氮原子之间的距离(d)在0.3到0.8纳米之间。该发明涉及由公式G定义的新的杂环化合物,它们的制备,包含它们的制药组合物以及它们作为治疗剂的用途,特别是在神经退行性或阿尔茨海默病的治疗中。
  • New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
    申请人:Institut National des Sciences Appliquees de Rouen (INSA)
    公开号:EP1731507A1
    公开(公告)日:2006-12-13
    The invention is related to compound which comprises at least one radical C=Y, Y being O or S, and an oxidable and non protonable nitrogen atom N wherein the distance (d) between the at least one carbon atom of the radical group C=Y and the nitrogen atom, when oxidized, is comprised between 0.3 and 0.8 nanometers. The invention is related to new heterocyclic compounds defined by formula G, their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of neurodegenerative or Alzheimer disease.
    本发明涉及由至少一个基团C=Y(Y为O或S)和一个可氧化且不可质子化的氮原子N组成的化合物,其中基团C=Y的至少一个碳原子与氮原子之间的距离(d)在氧化时介于0.3至0.8纳米之间。 本发明涉及由式 G 定义的新杂环化合物、 它们的制备、包含它们的药物组合物以及它们作为治疗剂的用途,特别是在治疗神经退行性疾病或阿尔茨海默病中的用途。
  • 1,4-substituted piperidine derivatives
    申请人:89BIO LTD
    公开号:US10221135B2
    公开(公告)日:2019-03-05
    Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    本文描述了根据式 I 的 1,4-取代的哌啶化合物,这些化合物已被证明具有脂肪酸合酶抑制剂的活性。本文还描述了含有所述 1,4-取代哌啶化合物的药物组合物,以及通过施用一种或多种本文所述化合物或药物制剂治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述化合物的方法,包括所述 1,4-取代的哌啶化合物和用于这些合成的合成中间体。
  • NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS
    申请人:Insa Rouen
    公开号:EP1868998A2
    公开(公告)日:2007-12-26
查看更多